{
  "video_id": "8P9nrkMF33w",
  "title": "Association for Molecular Pathology vs. Myriad Genetics - Arti Rai",
  "es": 0,
  "json": [
    {
      "index": 1,
      "start_time": 640.0,
      "end_time": 5720.0,
      "text": "Arti Rai: I will try to give you a relatively engaging"
    },
    {
      "index": 2,
      "start_time": 5720.0,
      "end_time": 11550.0,
      "text": "and short discussion so that we can have some time for questions. I will also, I&#39;m afraid,"
    },
    {
      "index": 3,
      "start_time": 11550.0,
      "end_time": 15510.0,
      "text": "use a few more words in my slides than you may be accustomed to. Lawyers -- and I&#39;m a"
    },
    {
      "index": 4,
      "start_time": 15510.0,
      "end_time": 21060.0,
      "text": "recovering lawyer -- do like words, and so there are more words than would be ideal."
    },
    {
      "index": 5,
      "start_time": 21060.0,
      "end_time": 23710.0,
      "text": "But the words end up being kind of important."
    },
    {
      "index": 6,
      "start_time": 23710.0,
      "end_time": 29689.0,
      "text": "So, as Eric has already indicated, the Supreme Court, on June 13th, having heard argument"
    },
    {
      "index": 7,
      "start_time": 29689.0,
      "end_time": 36000.0,
      "text": "on April 15th, decided that AMP versus Myriad Genetics, the challenge was brought by the"
    },
    {
      "index": 8,
      "start_time": 36000.0,
      "end_time": 41210.0,
      "text": "Association of Molecular Pathologists, represented by the ACLU and the Public Patent Foundation."
    },
    {
      "index": 9,
      "start_time": 41210.0,
      "end_time": 49329.0,
      "text": "In its ruling, the court, the Supreme Court, that is, held that not all gene patents are"
    },
    {
      "index": 10,
      "start_time": 49329.0,
      "end_time": 57160.0,
      "text": "alike, and I&#39;ll spend some time talking about what specifically they meant by not all gene"
    },
    {
      "index": 11,
      "start_time": 57160.0,
      "end_time": 63980.0,
      "text": "patents being alike. As it happens, they got into the -- for them, I think, what was really"
    },
    {
      "index": 12,
      "start_time": 63980.0,
      "end_time": 70070.0,
      "text": "tough sledding with respect to molecular biology, they had to distinguish between cDNA and gDNA,"
    },
    {
      "index": 13,
      "start_time": 70070.0,
      "end_time": 76100.0,
      "text": "which I suspect for Justice Thomas was something of a struggle. But he did an interesting job."
    },
    {
      "index": 14,
      "start_time": 76100.0,
      "end_time": 81140.0,
      "text": "So what I&#39;m going to do today, for those of you that don&#39;t necessarily spend their time"
    },
    {
      "index": 15,
      "start_time": 81140.0,
      "end_time": 85210.0,
      "text": "thinking a lot about patent law, and that may be many of you, is provide a little bit"
    },
    {
      "index": 16,
      "start_time": 85210.0,
      "end_time": 90649.0,
      "text": "of basic background on patent law, and also on gene patents in particular, and how they"
    },
    {
      "index": 17,
      "start_time": 90649.0,
      "end_time": 97729.0,
      "text": "emerged and why they emerged. Then I&#39;ll discuss the history of the Myriad case very briefly,"
    },
    {
      "index": 18,
      "start_time": 97729.0,
      "end_time": 104479.0,
      "text": "and also, its ultimate resolution at the Supreme Court. And finally, I&#39;ll discuss what the"
    },
    {
      "index": 19,
      "start_time": 104479.0,
      "end_time": 109079.0,
      "text": "case might mean going forward. That&#39;s very much a work in progress in terms of what it"
    },
    {
      "index": 20,
      "start_time": 109079.0,
      "end_time": 114420.0,
      "text": "means, and there are subsequent lawsuits that I will mention briefly as well."
    },
    {
      "index": 21,
      "start_time": 114420.0,
      "end_time": 119810.0,
      "text": "So, just in terms of background, this is Patents 101, and also, as it happens to be, Section"
    },
    {
      "index": 22,
      "start_time": 119810.0,
      "end_time": 127170.0,
      "text": "101 of the Patent Statute. That section has typically been interpreted very broadly to"
    },
    {
      "index": 23,
      "start_time": 127170.0,
      "end_time": 133230.0,
      "text": "cover basically anything under the sun made by man. That&#39;s a statement from the Legislative"
    },
    {
      "index": 24,
      "start_time": 133230.0,
      "end_time": 140230.0,
      "text": "History of the 1952 Patent Act. And the provision in the statute suggests as much -- suggests"
    },
    {
      "index": 25,
      "start_time": 140230.0,
      "end_time": 146000.0,
      "text": "that it&#39;s pretty broad in its scope, so any new and useful process machine, manufacturer,"
    },
    {
      "index": 26,
      "start_time": 146000.0,
      "end_time": 152709.0,
      "text": "or composition of matter is supposed to be encompassed within Section 101, which means,"
    },
    {
      "index": 27,
      "start_time": 152709.0,
      "end_time": 158640.0,
      "text": "basically, any new process or product. That said, there have been these long-standing"
    },
    {
      "index": 28,
      "start_time": 158640.0,
      "end_time": 164120.0,
      "text": "common law exceptions that the Supreme Court has enunciated, starting in the 19th century,"
    },
    {
      "index": 29,
      "start_time": 164120.0,
      "end_time": 168650.0,
      "text": "and by &quot;common law,&quot; I mean as contrasted with statutory law. Common law is the gloss"
    },
    {
      "index": 30,
      "start_time": 168650.0,
      "end_time": 172430.0,
      "text": "that courts put on the statutory law."
    },
    {
      "index": 31,
      "start_time": 172430.0,
      "end_time": 178690.0,
      "text": "And this common law gloss encompasses exceptions in the form of abstract ideas, laws of nature,"
    },
    {
      "index": 32,
      "start_time": 178690.0,
      "end_time": 184920.0,
      "text": "and products of nature. The exception at issue, specifically in the Myriad case, was products"
    },
    {
      "index": 33,
      "start_time": 184920.0,
      "end_time": 189810.0,
      "text": "of nature. However, as we will see, all of these three exceptions kind of run together"
    },
    {
      "index": 34,
      "start_time": 189810.0,
      "end_time": 194870.0,
      "text": "a little bit, and that becomes important for what the case means going forward."
    },
    {
      "index": 35,
      "start_time": 194870.0,
      "end_time": 200510.0,
      "text": "So the product of nature doctrine actually has an interesting history beyond the Supreme"
    },
    {
      "index": 36,
      "start_time": 200510.0,
      "end_time": 206939.0,
      "text": "Court, and in most ways, the most important expositor of the product of nature doctrine"
    },
    {
      "index": 37,
      "start_time": 206939.0,
      "end_time": 213560.0,
      "text": "was a judge by the name of Learned Hand -- that was really his name. Judge Hand, albeit only"
    },
    {
      "index": 38,
      "start_time": 213560.0,
      "end_time": 219299.0,
      "text": "a district court judge at the time, rendered what is one of the most important decisions"
    },
    {
      "index": 39,
      "start_time": 219299.0,
      "end_time": 226120.0,
      "text": "in the product of nature space in a case called Parke-Davis that was decided in 1911. In that"
    },
    {
      "index": 40,
      "start_time": 226120.0,
      "end_time": 236409.0,
      "text": "case, he determined that isolated or purified adrenaline represented patent-eligible subject"
    },
    {
      "index": 41,
      "start_time": 236409.0,
      "end_time": 243829.0,
      "text": "matter, and in his view, this was not a product of nature -- isolated adrenaline represented"
    },
    {
      "index": 42,
      "start_time": 243829.0,
      "end_time": 248519.0,
      "text": "one patent, purified adrenaline represented another -- this was not a product of nature"
    },
    {
      "index": 43,
      "start_time": 248519.0,
      "end_time": 253829.0,
      "text": "because it was, and this was a quote from the opinion, &quot;For every practical purpose"
    },
    {
      "index": 44,
      "start_time": 253829.0,
      "end_time": 262830.0,
      "text": "a new thing commercially and therapeutically,&quot; unquote. Because this language resonated with"
    },
    {
      "index": 45,
      "start_time": 262830.0,
      "end_time": 267890.0,
      "text": "some of the commercial instincts that patent lawyers have, they really have seized upon"
    },
    {
      "index": 46,
      "start_time": 267890.0,
      "end_time": 275070.0,
      "text": "this language for more than a century as representing what they determine to be the narrow exception"
    },
    {
      "index": 47,
      "start_time": 275070.0,
      "end_time": 280080.0,
      "text": "that product of nature represents; in other words, anything that is a new thing, commercially"
    },
    {
      "index": 48,
      "start_time": 280080.0,
      "end_time": 287490.0,
      "text": "or therapeutically, for many in the patent lawyer community, is not a product of nature."
    },
    {
      "index": 49,
      "start_time": 287490.0,
      "end_time": 294850.0,
      "text": "This view of the expansive realm of what is within patentable subject matter, and therefore"
    },
    {
      "index": 50,
      "start_time": 294850.0,
      "end_time": 300660.0,
      "text": "not a product of nature, was, to some extent, reaffirmed in the patent lawyer community"
    },
    {
      "index": 51,
      "start_time": 300660.0,
      "end_time": 305850.0,
      "text": "in the Supreme Court case of Diamond vs. Chakrabarty that some of you may have heard of. That case"
    },
    {
      "index": 52,
      "start_time": 305850.0,
      "end_time": 313980.0,
      "text": "involved a recombinant bacterium, a bacterium that had two or more stable energy-generating"
    },
    {
      "index": 53,
      "start_time": 313980.0,
      "end_time": 321210.0,
      "text": "plasmids put into it, each plasmid constituting a separate hydrocarbon degredative pathway."
    },
    {
      "index": 54,
      "start_time": 321210.0,
      "end_time": 326490.0,
      "text": "In that case, the Supreme Court, in a divided opinion, determined that this was not a product"
    },
    {
      "index": 55,
      "start_time": 326490.0,
      "end_time": 331390.0,
      "text": "of nature because &quot;It was markedly different,&quot; quote, unquote -- again, these are the words"
    },
    {
      "index": 56,
      "start_time": 331390.0,
      "end_time": 337870.0,
      "text": "that the court used -- from anything found in nature. Not quite as expansive as the Parke-Davis"
    },
    {
      "index": 57,
      "start_time": 337870.0,
      "end_time": 345490.0,
      "text": "opinion which suggested that if what one had done provided something commercially useful,"
    },
    {
      "index": 58,
      "start_time": 345490.0,
      "end_time": 349210.0,
      "text": "it represented patent-eligible subject manner. So Diamond vs. Chakrabarty was not quite as"
    },
    {
      "index": 59,
      "start_time": 349210.0,
      "end_time": 356050.0,
      "text": "expansive, but the combination was taken by patent lawyers and the nascent biotech industries"
    },
    {
      "index": 60,
      "start_time": 356050.0,
      "end_time": 364150.0,
      "text": "to mean that basically anything that was isolated or purified could be patent eligible, and"
    },
    {
      "index": 61,
      "start_time": 364150.0,
      "end_time": 366770.0,
      "text": "that included gene sequences."
    },
    {
      "index": 62,
      "start_time": 366770.0,
      "end_time": 371560.0,
      "text": "So the first &quot;gene patents,&quot; quote, unquote -- and that is, to some extent, now a term"
    },
    {
      "index": 63,
      "start_time": 371560.0,
      "end_time": 374800.0,
      "text": "of art because they mean different things to different people, that term means different"
    },
    {
      "index": 64,
      "start_time": 374800.0,
      "end_time": 382490.0,
      "text": "things to different people -- covered cDNA, in other words, DNA with introns excised that"
    },
    {
      "index": 65,
      "start_time": 382490.0,
      "end_time": 389560.0,
      "text": "was intended to be used to generate therapeutics and cover therapeutics. One of the reasons,"
    },
    {
      "index": 66,
      "start_time": 389560.0,
      "end_time": 395470.0,
      "text": "in part at least, these particular cDNA patents were not controversial was that they were"
    },
    {
      "index": 67,
      "start_time": 395470.0,
      "end_time": 402570.0,
      "text": "intended to cover a scope of genetic research and development, an area of genetic research"
    },
    {
      "index": 68,
      "start_time": 402570.0,
      "end_time": 408310.0,
      "text": "and development, i.e. therapeutics, that looked very much like what had been patent eligible"
    },
    {
      "index": 69,
      "start_time": 408310.0,
      "end_time": 413520.0,
      "text": "in the past in terms of small molecules. So these were just large molecules as opposed"
    },
    {
      "index": 70,
      "start_time": 413520.0,
      "end_time": 414350.0,
      "text": "to small molecules."
    },
    {
      "index": 71,
      "start_time": 414350.0,
      "end_time": 419650.0,
      "text": "And so when, for example, when some of these patents began to issue in the early &#39;80s,"
    },
    {
      "index": 72,
      "start_time": 419650.0,
      "end_time": 425770.0,
      "text": "and Amgen got one of these classic patents on DNA sequences encoding erythropoietin,"
    },
    {
      "index": 73,
      "start_time": 425770.0,
      "end_time": 431970.0,
      "text": "cDNA encoding erythropoietin in 1987, a patent that subsequently allowed it to make tens"
    },
    {
      "index": 74,
      "start_time": 431970.0,
      "end_time": 438740.0,
      "text": "of billions of dollars in revenue over the course of about 23 years, that wasn&#39;t considered"
    },
    {
      "index": 75,
      "start_time": 438740.0,
      "end_time": 445960.0,
      "text": "particularly controversial, at least certainly not in the patent bar community, and even"
    },
    {
      "index": 76,
      "start_time": 445960.0,
      "end_time": 451870.0,
      "text": "among the larger community, the idea of DNA sequences that would be patentable but would"
    },
    {
      "index": 77,
      "start_time": 451870.0,
      "end_time": 458860.0,
      "text": "correlate therapeutics wasn&#39;t particularly controversial. And this patent was a subject"
    },
    {
      "index": 78,
      "start_time": 458860.0,
      "end_time": 463190.0,
      "text": "of litigation; however, none of the litigation involved the issue of whether or not this"
    },
    {
      "index": 79,
      "start_time": 463190.0,
      "end_time": 468770.0,
      "text": "constituted patent-eligible subject matter, probably in part because everyone in the litigation"
    },
    {
      "index": 80,
      "start_time": 468770.0,
      "end_time": 474620.0,
      "text": "had their own gene patents. So Amgen sued Genetics Institute, and Transkaryotic, and"
    },
    {
      "index": 81,
      "start_time": 474620.0,
      "end_time": 478300.0,
      "text": "Roche, and, of course, all of those entities had their own gene patents to defend, and"
    },
    {
      "index": 82,
      "start_time": 478300.0,
      "end_time": 483650.0,
      "text": "so there was no incentive on the part of anyone to say that gene patents were not patent-eligible"
    },
    {
      "index": 83,
      "start_time": 483650.0,
      "end_time": 487330.0,
      "text": "subject matter."
    },
    {
      "index": 84,
      "start_time": 487330.0,
      "end_time": 492590.0,
      "text": "Controversies began to emerge however when patents issued -- and some of these patents"
    },
    {
      "index": 85,
      "start_time": 492590.0,
      "end_time": 497170.0,
      "text": "issued relatively early on, including the Myriad patents -- that were later interpreted"
    },
    {
      "index": 86,
      "start_time": 497170.0,
      "end_time": 503660.0,
      "text": "to cover not just therapeutics but also diagnostics. Obviously, like all patents, patents that"
    },
    {
      "index": 87,
      "start_time": 503660.0,
      "end_time": 508710.0,
      "text": "covered diagnostics increase costs, or have the potential to increase costs, and restrict"
    },
    {
      "index": 88,
      "start_time": 508710.0,
      "end_time": 514990.0,
      "text": "access. The argument, or one of the reasons people were more concerned about patents covering"
    },
    {
      "index": 89,
      "start_time": 514990.0,
      "end_time": 521159.0,
      "text": "diagnostics was, in particular, with the respect to laboratory-developed testing of the sort"
    },
    {
      "index": 90,
      "start_time": 521159.0,
      "end_time": 528690.0,
      "text": "that Myriad does. That&#39;s not currently FDA regulated, so patents were seen as less necessary"
    },
    {
      "index": 91,
      "start_time": 528690.0,
      "end_time": 537010.0,
      "text": "for purposes of providing incentive to get a particular product to market. If one had"
    },
    {
      "index": 92,
      "start_time": 537010.0,
      "end_time": 541880.0,
      "text": "the relevant gene, it wasn&#39;t considered that expensive to then start doing testing on the"
    },
    {
      "index": 93,
      "start_time": 541880.0,
      "end_time": 546770.0,
      "text": "gene, and in point of fact, in a lot of the cases, testing started before the patents"
    },
    {
      "index": 94,
      "start_time": 546770.0,
      "end_time": 553640.0,
      "text": "emerged. And the patents ended up being used to shut down certain testing -- diagnostic"
    },
    {
      "index": 95,
      "start_time": 553640.0,
      "end_time": 555320.0,
      "text": "testing laboratories."
    },
    {
      "index": 96,
      "start_time": 555320.0,
      "end_time": 558670.0,
      "text": "In addition there was a substantial amount of federal funding involved with some of these"
    },
    {
      "index": 97,
      "start_time": 558670.0,
      "end_time": 563170.0,
      "text": "patents, including in the Myriad case itself, and we&#39;ll talk about that a little bit more"
    },
    {
      "index": 98,
      "start_time": 563170.0,
      "end_time": 567770.0,
      "text": "-- I&#39;ll talk about that a little bit more towards the end."
    },
    {
      "index": 99,
      "start_time": 567770.0,
      "end_time": 576470.0,
      "text": "So the access questions in particular, relative to the diminished need for an affirmative"
    },
    {
      "index": 100,
      "start_time": 576470.0,
      "end_time": 583940.0,
      "text": "incentive provided by patents, were the focus of this very prominent report issued by the"
    },
    {
      "index": 101,
      "start_time": 583940.0,
      "end_time": 588900.0,
      "text": "Secretary&#39;s Advisory Committee on Genetics, Health, and Society, and our own Jim Evans"
    },
    {
      "index": 102,
      "start_time": 588900.0,
      "end_time": 596950.0,
      "text": "was at the helm of that particular report. The focus there was not only on initial access"
    },
    {
      "index": 103,
      "start_time": 596950.0,
      "end_time": 603310.0,
      "text": "but also on problems for women who wanted to get second opinion testing, with the respect"
    },
    {
      "index": 104,
      "start_time": 603310.0,
      "end_time": 611720.0,
      "text": "to BRCA-1 and BRCA-2. The Secretary&#39;s Advisory Committee was -- relatedly was concerned about"
    },
    {
      "index": 105,
      "start_time": 611720.0,
      "end_time": 617160.0,
      "text": "whether sole providers of genetic diagnostic testing, such as Myriad, but also other providers,"
    },
    {
      "index": 106,
      "start_time": 617160.0,
      "end_time": 624730.0,
      "text": "like Athena, had the optimal incentive to work aggressively with all types of insurers,"
    },
    {
      "index": 107,
      "start_time": 624730.0,
      "end_time": 630840.0,
      "text": "in particular insurers that might cover less well off populations, such as state Medicaid"
    },
    {
      "index": 108,
      "start_time": 630840.0,
      "end_time": 632930.0,
      "text": "providers."
    },
    {
      "index": 109,
      "start_time": 632930.0,
      "end_time": 638270.0,
      "text": "So the report discussed not only the BRCA-1 and BRCA-2 patents, but also patents on genes"
    },
    {
      "index": 110,
      "start_time": 638270.0,
      "end_time": 644080.0,
      "text": "implicated in certain types of colon cancer, Alzheimer&#39;s disease, spinocerebellar ataxia,"
    },
    {
      "index": 111,
      "start_time": 644080.0,
      "end_time": 653030.0,
      "text": "and long QT syndrome. This report was issued in 2010 after Myriad had been sued by the"
    },
    {
      "index": 112,
      "start_time": 653030.0,
      "end_time": 660100.0,
      "text": "Association of Molecular Pathologists, represented by the ACLU in district court. So it came"
    },
    {
      "index": 113,
      "start_time": 660100.0,
      "end_time": 664690.0,
      "text": "out as this debate was, for the first time, the Section 101 debate, was, for the first"
    },
    {
      "index": 114,
      "start_time": 664690.0,
      "end_time": 670420.0,
      "text": "time, unfolding in litigation. Again, never before had a Section 101 challenge been brought"
    },
    {
      "index": 115,
      "start_time": 670420.0,
      "end_time": 674290.0,
      "text": "to gene patents of any sort."
    },
    {
      "index": 116,
      "start_time": 674290.0,
      "end_time": 680930.0,
      "text": "So we get to the Myriad gene patent litigation. Myriad, I think, was chosen by the ACLU for"
    },
    {
      "index": 117,
      "start_time": 680930.0,
      "end_time": 686130.0,
      "text": "a number of reasons, one of which was it was the provider that was most aggressive in terms"
    },
    {
      "index": 118,
      "start_time": 686130.0,
      "end_time": 692340.0,
      "text": "of asserting its patents against providers who considered themselves to be doing clinical"
    },
    {
      "index": 119,
      "start_time": 692340.0,
      "end_time": 701520.0,
      "text": "research in addition to providing patient care. In this particular case, the ACLU/AMP"
    },
    {
      "index": 120,
      "start_time": 701520.0,
      "end_time": 708240.0,
      "text": "challenged 15 claims in seven patents. Many of these patents, at it happens, were initially"
    },
    {
      "index": 121,
      "start_time": 708240.0,
      "end_time": 712980.0,
      "text": "owned and exclusively licensed by the University of Utah, which had received a fair amount"
    },
    {
      "index": 122,
      "start_time": 712980.0,
      "end_time": 718710.0,
      "text": "of NIH funding, particularly early on. NIH was actually the co-owner of one of the patents."
    },
    {
      "index": 123,
      "start_time": 718710.0,
      "end_time": 724430.0,
      "text": "So this is -- the federal funding issue was intimately involved with this particular case."
    },
    {
      "index": 124,
      "start_time": 724430.0,
      "end_time": 730540.0,
      "text": "The litigation, notably, however, the litigation strategy by the ACLU didn&#39;t focus on access"
    },
    {
      "index": 125,
      "start_time": 730540.0,
      "end_time": 736490.0,
      "text": "at all. And I think the ACLU determined that they were going to kind of talk the typical"
    },
    {
      "index": 126,
      "start_time": 736490.0,
      "end_time": 742180.0,
      "text": "patent lawyer&#39;s line of access -- not access, but innovation. And so the arguments that"
    },
    {
      "index": 127,
      "start_time": 742180.0,
      "end_time": 748240.0,
      "text": "were used very much were along the lines of these patents were diminishing innovation"
    },
    {
      "index": 128,
      "start_time": 748240.0,
      "end_time": 751720.0,
      "text": "in the area of genomic research and development."
    },
    {
      "index": 129,
      "start_time": 751720.0,
      "end_time": 759310.0,
      "text": "In point of fact, at the federal circuit, Judge Lourie stated what I think all the judges"
    },
    {
      "index": 130,
      "start_time": 759310.0,
      "end_time": 764970.0,
      "text": "in this litigation agreed with, at least implicitly, by not saying anything about access. He&#39;s"
    },
    {
      "index": 131,
      "start_time": 764970.0,
      "end_time": 769710.0,
      "text": "stated explicitly, and he wrote the majority opinion, &quot;This appeal is not about whether"
    },
    {
      "index": 132,
      "start_time": 769710.0,
      "end_time": 774630.0,
      "text": "individuals suspected of having an increase risk of developing breast cancer are entitled"
    },
    {
      "index": 133,
      "start_time": 774630.0,
      "end_time": 780770.0,
      "text": "to a second opinion.&quot; Similarly, even the dissent in the federal circuit case, before"
    },
    {
      "index": 134,
      "start_time": 780770.0,
      "end_time": 787650.0,
      "text": "it got to the Supreme Court, really focused on innovation, and the dissent drew a distinction"
    },
    {
      "index": 135,
      "start_time": 787650.0,
      "end_time": 796529.0,
      "text": "between cDNA and gDNA that had been alluded to in the Secretary&#39;s Advisory Committee report,"
    },
    {
      "index": 136,
      "start_time": 796529.0,
      "end_time": 804190.0,
      "text": "but for the purposes of saying that cDNA patents wouldn&#39;t impede research and development in"
    },
    {
      "index": 137,
      "start_time": 804190.0,
      "end_time": 809390.0,
      "text": "genome sequencing, whereas gDNA patents might. So, again, very much focused on innovation."
    },
    {
      "index": 138,
      "start_time": 809390.0,
      "end_time": 816540.0,
      "text": "The Department of Justice&#39;s intervention in this case at the federal circuit level also"
    },
    {
      "index": 139,
      "start_time": 816540.0,
      "end_time": 823330.0,
      "text": "drew the cDNA/gDNA distinction with a focus on follow-on innovation, and Eric has mentioned"
    },
    {
      "index": 140,
      "start_time": 823330.0,
      "end_time": 831770.0,
      "text": "that NIH was influential in crafting the U.S. government&#39;s opinion. I think that&#39;s an understatement"
    },
    {
      "index": 141,
      "start_time": 831770.0,
      "end_time": 838420.0,
      "text": "in many ways; NIH was a critical player, and NIH, as it happens, has had a long history"
    },
    {
      "index": 142,
      "start_time": 838420.0,
      "end_time": 846000.0,
      "text": "in helping to shape genomic patent policy starting in the late -- the end of the 20th"
    },
    {
      "index": 143,
      "start_time": 846000.0,
      "end_time": 851520.0,
      "text": "century with the so-called utility and written description guidelines that were very significantly"
    },
    {
      "index": 144,
      "start_time": 851520.0,
      "end_time": 857600.0,
      "text": "shaped by NIH, and I think had a very positive influence in terms of making sure that genomic"
    },
    {
      "index": 145,
      "start_time": 857600.0,
      "end_time": 863140.0,
      "text": "innovation was not impeded by patents. All of this, by the way, is drawn out in exhaustive"
    },
    {
      "index": 146,
      "start_time": 863140.0,
      "end_time": 867910.0,
      "text": "detail in many more words in a Duke Law Journal article; the role of NIH over the last 15"
    },
    {
      "index": 147,
      "start_time": 867910.0,
      "end_time": 871839.0,
      "text": "years or so is drawn out in exhaustive detail in this Duke Law Journal that were published"
    },
    {
      "index": 148,
      "start_time": 871839.0,
      "end_time": 879560.0,
      "text": "last year, so if you&#39;re interested, you can go to that. But, again, the focus on innovation,"
    },
    {
      "index": 149,
      "start_time": 879560.0,
      "end_time": 884330.0,
      "text": "and the fact that cDNA patents are unlikely to impede innovation whereas gDNA patents"
    },
    {
      "index": 150,
      "start_time": 884330.0,
      "end_time": 888990.0,
      "text": "might well impede whole genome sequencing."
    },
    {
      "index": 151,
      "start_time": 888990.0,
      "end_time": 894470.0,
      "text": "At the Supreme Court only claims at issue were the so-called product claims; the process"
    },
    {
      "index": 152,
      "start_time": 894470.0,
      "end_time": 899470.0,
      "text": "claims had been taken out of the litigation, so there were only nine composition of matter"
    },
    {
      "index": 153,
      "start_time": 899470.0,
      "end_time": 905700.0,
      "text": "or product claims at issue. The Supreme Court, like Judge Bryson in dissent below, like the"
    },
    {
      "index": 154,
      "start_time": 905700.0,
      "end_time": 912300.0,
      "text": "solicitor general, and like Eric Lander, who&#39;s also been previously mentioned, adopted a"
    },
    {
      "index": 155,
      "start_time": 912300.0,
      "end_time": 919440.0,
      "text": "cDNA versus gDNA distinction. Unfortunately, the court&#39;s opinion was not as clear as to"
    },
    {
      "index": 156,
      "start_time": 919440.0,
      "end_time": 925630.0,
      "text": "why it was adopting this distinction as it might have been. It did say that cDNA was"
    },
    {
      "index": 157,
      "start_time": 925630.0,
      "end_time": 934620.0,
      "text": "not naturally occurring, and thereby implicitly suggesting that gDNA could be naturally occurring,"
    },
    {
      "index": 158,
      "start_time": 934620.0,
      "end_time": 939800.0,
      "text": "but it didn&#39;t really specifically say that, and we can only infer based upon the fact"
    },
    {
      "index": 159,
      "start_time": 939800.0,
      "end_time": 945670.0,
      "text": "that Eric Lander&#39;s brief was mentioned about six times in oral argument, that they relied"
    },
    {
      "index": 160,
      "start_time": 945670.0,
      "end_time": 954899.0,
      "text": "upon Eric Lander&#39;s brief&#39;s argument about gDNA being found -- isolated gDNA being found"
    },
    {
      "index": 161,
      "start_time": 954899.0,
      "end_time": 962029.0,
      "text": "in fetal DNA and also upon cell death. So, unfortunately, though, the opinion doesn&#39;t"
    },
    {
      "index": 162,
      "start_time": 962029.0,
      "end_time": 968149.0,
      "text": "explicitly say that, so that a little bit hard to parse on the why gDNA is naturally"
    },
    {
      "index": 163,
      "start_time": 968149.0,
      "end_time": 971430.0,
      "text": "occurring versus cDNA is not."
    },
    {
      "index": 164,
      "start_time": 971430.0,
      "end_time": 975680.0,
      "text": "Another piece of the opinion focuses -- and this important going forward for purposes"
    },
    {
      "index": 165,
      "start_time": 975680.0,
      "end_time": 983420.0,
      "text": "of what the opinion means for future patenting, and also existing patents outside the cDNA/gDNA"
    },
    {
      "index": 166,
      "start_time": 983420.0,
      "end_time": 989140.0,
      "text": "context -- focuses on the so-called information versus chemical distinction. This was a distinction"
    },
    {
      "index": 167,
      "start_time": 989140.0,
      "end_time": 995149.0,
      "text": "that was drawn by the district court judge in this case, and the Supreme Court picked"
    },
    {
      "index": 168,
      "start_time": 995149.0,
      "end_time": 1003860.0,
      "text": "it up again. Again, however, it didn&#39;t completely connect the dots as to why cDNA versus gDNA"
    },
    {
      "index": 169,
      "start_time": 1003860.0,
      "end_time": 1008089.0,
      "text": "mapped onto that distinction. In point of fact, the court even suggested -- the Supreme"
    },
    {
      "index": 170,
      "start_time": 1008090.0,
      "end_time": 1014681.0,
      "text": "Court, that is -- that cDNA and gDNA both covered information suggesting that, however,"
    },
    {
      "index": 171,
      "start_time": 1014680.0,
      "end_time": 1020270.0,
      "text": "that, nonetheless, cDNA was less problematic in terms of the informational claims it made."
    },
    {
      "index": 172,
      "start_time": 1020270.0,
      "end_time": 1027750.0,
      "text": "All we can assume, and this is what I would assume and have argued should be the interpretation"
    },
    {
      "index": 173,
      "start_time": 1027750.0,
      "end_time": 1033850.0,
      "text": "of the case, is that Justice Thomas had been impressed by Eric Lander and the solicitor"
    },
    {
      "index": 174,
      "start_time": 1033849.9999999999,
      "end_time": 1039009.9999999999,
      "text": "general, and their statements that cDNA, even though it claimed information or could be"
    },
    {
      "index": 175,
      "start_time": 1039010.0,
      "end_time": 1044520.0,
      "text": "seen as claiming information, didn&#39;t -- those sorts of things wouldn&#39;t impede future follow-on"
    },
    {
      "index": 176,
      "start_time": 1044520.0,
      "end_time": 1051160.0,
      "text": "innovation in the same way as gDNA. And Bob Cook-Deegan and I put that interpretation"
    },
    {
      "index": 177,
      "start_time": 1051160.0,
      "end_time": 1054620.0,
      "text": "on the case in a Science article that just came out a couple of months ago, and so we&#39;re"
    },
    {
      "index": 178,
      "start_time": 1054620.0,
      "end_time": 1061860.0,
      "text": "hoping that the lower courts will take that as a plausible interpretation that said the"
    },
    {
      "index": 179,
      "start_time": 1061860.0,
      "end_time": 1066710.0,
      "text": "Supreme Court unfortunately wasn&#39;t as clear as it could have been."
    },
    {
      "index": 180,
      "start_time": 1066710.0,
      "end_time": 1071800.0,
      "text": "So in the immediate aftermath of the case, I suspect some of you know this already, on"
    },
    {
      "index": 181,
      "start_time": 1071800.0,
      "end_time": 1078630.0,
      "text": "the day of the case being decided itself, a whole bunch of providers, a whole array"
    },
    {
      "index": 182,
      "start_time": 1078630.0,
      "end_time": 1085630.0,
      "text": "of providers, announced that they would be testing for BRCA-1 and BRCA-2 mutations. Ambry"
    },
    {
      "index": 183,
      "start_time": 1085630.0,
      "end_time": 1093870.0,
      "text": "in particular announced a price that was about a 50 percent reduction from the Myriad price,"
    },
    {
      "index": 184,
      "start_time": 1093870.0,
      "end_time": 1099580.0,
      "text": "and perhaps not surprisingly, Ambry was the first provider that was sued. So Myriad, as"
    },
    {
      "index": 185,
      "start_time": 1099580.0,
      "end_time": 1105470.0,
      "text": "it happens, had been alleging that it had all these other patents it could use even"
    },
    {
      "index": 186,
      "start_time": 1105470.0,
      "end_time": 1111490.0,
      "text": "if they lost the case to the Supreme Court, and nobody necessarily took them that seriously,"
    },
    {
      "index": 187,
      "start_time": 1111490.0,
      "end_time": 1115420.0,
      "text": "but it turned out they were planning to sue on those other patents if they lost to the"
    },
    {
      "index": 188,
      "start_time": 1115420.0,
      "end_time": 1120630.0,
      "text": "Supreme Court, and they did, in fact, sue on 10 other patents involving dozens of claims."
    },
    {
      "index": 189,
      "start_time": 1120630.0,
      "end_time": 1125390.0,
      "text": "None of these claims, with the exception on one that we can talk about, was at issue in"
    },
    {
      "index": 190,
      "start_time": 1125390.0,
      "end_time": 1131390.0,
      "text": "the Supreme Court case. Both these suits -- they also brought a suit against Gene-by-Gene -- both"
    },
    {
      "index": 191,
      "start_time": 1131390.0,
      "end_time": 1135890.0,
      "text": "these suits, for them, have a bit -- for Myriad, have a bit of a home-court advantage in that"
    },
    {
      "index": 192,
      "start_time": 1135890.0,
      "end_time": 1141780.0,
      "text": "they&#39;re being brought in Utah district court, and Myriad is obviously based in Utah."
    },
    {
      "index": 193,
      "start_time": 1141780.0,
      "end_time": 1146600.0,
      "text": "So assessing the suits, I won&#39;t say too much here for fear of being proven wrong in the"
    },
    {
      "index": 194,
      "start_time": 1146600.0,
      "end_time": 1152050.0,
      "text": "next few months when the Supreme -- the district court decides the cases, but these claims"
    },
    {
      "index": 195,
      "start_time": 1152050.0,
      "end_time": 1159750.0,
      "text": "all cover basically either methods for sequence amplification, and then sequencing, and then"
    },
    {
      "index": 196,
      "start_time": 1159750.0,
      "end_time": 1167880.0,
      "text": "comparison with wild-type, a lot of method claims, and then a few primers plus PCR claims."
    },
    {
      "index": 197,
      "start_time": 1167880.0,
      "end_time": 1176240.0,
      "text": "The determination of how these claims will be adjudicated, I think, is anyone&#39;s guess,"
    },
    {
      "index": 198,
      "start_time": 1176240.0,
      "end_time": 1179900.0,
      "text": "but I think that what the court will have to do -- the district court at the initial"
    },
    {
      "index": 199,
      "start_time": 1179900.0,
      "end_time": 1184250.0,
      "text": "level, and obviously, this case will go to the federal circuit which hears all appeals"
    },
    {
      "index": 200,
      "start_time": 1184250.0,
      "end_time": 1188270.0,
      "text": "in the patent cases, and then maybe even back to the Supreme Court -- the determination"
    },
    {
      "index": 201,
      "start_time": 1188270.0,
      "end_time": 1192760.0,
      "text": "of what the court -- district court will do, I think, will be based on a combination of"
    },
    {
      "index": 202,
      "start_time": 1192760.0,
      "end_time": 1198480.0,
      "text": "the Myriad case, and then also a case -- another Section 101 case the Supreme Court decided"
    },
    {
      "index": 203,
      "start_time": 1198480.0,
      "end_time": 1203270.0,
      "text": "last year, called Mayo versus Prometheus."
    },
    {
      "index": 204,
      "start_time": 1203270.0,
      "end_time": 1209630.0,
      "text": "Some would say that the combination of those two cases means that these claims that Myriad"
    },
    {
      "index": 205,
      "start_time": 1209630.0,
      "end_time": 1216870.0,
      "text": "is bringing are likely invalid because they don&#39;t require any real inventive activity"
    },
    {
      "index": 206,
      "start_time": 1216870.0,
      "end_time": 1222299.0,
      "text": "-- that&#39;s the term of art that was used in the Mayo case -- beyond a law of nature or"
    },
    {
      "index": 207,
      "start_time": 1222300.0,
      "end_time": 1228601.0,
      "text": "a product of nature. That said, one could argue, and Bob and I make this point in our"
    },
    {
      "index": 208,
      "start_time": 1228600.0,
      "end_time": 1234580.0,
      "text": "Science article, that Myriad could be seen as walking back Mayo versus Prometheus a little"
    },
    {
      "index": 209,
      "start_time": 1234580.0,
      "end_time": 1241320.0,
      "text": "bit because cDNA, arguably, is nothing more than non-inventive routine activity applied"
    },
    {
      "index": 210,
      "start_time": 1241320.0,
      "end_time": 1249730.0,
      "text": "to a product of nature, i.e. DNA. So whether the lower courts will -- how they&#39;ll interpret"
    },
    {
      "index": 211,
      "start_time": 1249730.0,
      "end_time": 1253630.0,
      "text": "the combination of Myriad and Mayo versus Prometheus, I think, is going to be very interesting"
    },
    {
      "index": 212,
      "start_time": 1253630.0,
      "end_time": 1260400.0,
      "text": "to see. And the key question will be, is inventive activity beyond a law or product of nature"
    },
    {
      "index": 213,
      "start_time": 1260400.0,
      "end_time": 1263820.0,
      "text": "always required, and I think the Supreme Court has, frankly, left that question a little"
    },
    {
      "index": 214,
      "start_time": 1263820.0,
      "end_time": 1264990.0,
      "text": "bit open."
    },
    {
      "index": 215,
      "start_time": 1264990.0,
      "end_time": 1272120.0,
      "text": "Ambry has counterclaimed. Frankly, I think that its counterclaims on validity are quite"
    },
    {
      "index": 216,
      "start_time": 1272120.0,
      "end_time": 1280429.0,
      "text": "plausible. It also argues a variety of anti-trust violations by Myriad. I think those allegations"
    },
    {
      "index": 217,
      "start_time": 1280430.0,
      "end_time": 1284571.0,
      "text": "are less clear to me, at least, or the basis for those allegations is less clear to me."
    },
    {
      "index": 218,
      "start_time": 1284570.0,
      "end_time": 1291679.0,
      "text": "They use Section two of the Sherman Act and talk about monopolization, however, patents,"
    },
    {
      "index": 219,
      "start_time": 1291680.0,
      "end_time": 1297421.0,
      "text": "by definition in some cases, represent legitimate monopolies. So I&#39;m not sure that the anti-trust"
    },
    {
      "index": 220,
      "start_time": 1297420.0,
      "end_time": 1304480.0,
      "text": "claims, based upon the patents themselves, are necessarily valid. Another piece of the"
    },
    {
      "index": 221,
      "start_time": 1304480.0,
      "end_time": 1309620.0,
      "text": "puzzle which is very interesting and important is all of this data that Myriad has, mostly"
    },
    {
      "index": 222,
      "start_time": 1309620.0,
      "end_time": 1318179.0,
      "text": "secret since 2006, however -- and I&#39;ll talk about that in a moment -- however, the Ambry"
    },
    {
      "index": 223,
      "start_time": 1318180.0,
      "end_time": 1322861.0,
      "text": "brief doesn&#39;t specifically link that data issue with the anti-trust question, which"
    },
    {
      "index": 224,
      "start_time": 1322860.0,
      "end_time": 1327950.0,
      "text": "I think would be a very interesting argument to make, and presumably, they will, in further"
    },
    {
      "index": 225,
      "start_time": 1327950.0,
      "end_time": 1333240.0,
      "text": "briefing on that question, draw that link. The data, I think at this stage, are arguably"
    },
    {
      "index": 226,
      "start_time": 1333240.0,
      "end_time": 1338450.0,
      "text": "more important than the soon-to-expire patents, these particular patents, even the ones that"
    },
    {
      "index": 227,
      "start_time": 1338450.0,
      "end_time": 1342950.0,
      "text": "Myriad is suing upon are going to expire in the next few years. So the data is going to"
    },
    {
      "index": 228,
      "start_time": 1342950.0,
      "end_time": 1349549.0,
      "text": "be the competitive advantage that Myriad has going forward, at least for the longer term."
    },
    {
      "index": 229,
      "start_time": 1349550.0,
      "end_time": 1357631.0,
      "text": "And that brings us to that data issue. Myriad itself, in its argumentation against Ambry"
    },
    {
      "index": 230,
      "start_time": 1357630.0,
      "end_time": 1363850.0,
      "text": "and Gene-by-Gene, is actually using the data as a bit of a club to argue for a permanent"
    },
    {
      "index": 231,
      "start_time": 1363850.0,
      "end_time": 1369910.0,
      "text": "-- a preliminary, and then a permanent injunction against Ambry and Gene-by-Gene, saying that"
    },
    {
      "index": 232,
      "start_time": 1369910.0,
      "end_time": 1377030.0,
      "text": "Ambry is likely to have a variants of unknown significance rate of 25 to 30 percent, much"
    },
    {
      "index": 233,
      "start_time": 1377030.0,
      "end_time": 1383530.0,
      "text": "worse than Myriad&#39;s 3 percent rate, and therefore, it would actually harm the public to have"
    },
    {
      "index": 234,
      "start_time": 1383530.0,
      "end_time": 1390260.0,
      "text": "Ambry and other providers testing. As you probably know, Myriad, however, has stopped"
    },
    {
      "index": 235,
      "start_time": 1390260.0,
      "end_time": 1396480.0,
      "text": "contributing to public databases, it stopped contributing to the Breast Cancer Information"
    },
    {
      "index": 236,
      "start_time": 1396480.0,
      "end_time": 1404929.0,
      "text": "Core in 2005, and more generally, the larger scientific community hasn&#39;t had access to"
    },
    {
      "index": 237,
      "start_time": 1404930.0,
      "end_time": 1409101.0,
      "text": "the Myriad databases since 2006."
    },
    {
      "index": 238,
      "start_time": 1409100.0,
      "end_time": 1417940.0,
      "text": "So one question is, what will happen in respect to this data? And there are efforts already"
    },
    {
      "index": 239,
      "start_time": 1417940.0,
      "end_time": 1424340.0,
      "text": "afoot, and our own Robert Nussbaum is intimately involved with one of them, to quote, unquote,"
    },
    {
      "index": 240,
      "start_time": 1424340.0,
      "end_time": 1430410.0,
      "text": "&quot;free the data.&quot; So the Sharing Clinical Reports Project out of UCSF, working with the Genetic"
    },
    {
      "index": 241,
      "start_time": 1430410.0,
      "end_time": 1439290.0,
      "text": "Alliance, is asking patients and clinicians to submit to de-identified data that has been"
    },
    {
      "index": 242,
      "start_time": 1439290.0,
      "end_time": 1447630.0,
      "text": "received from Myriad after Myriad&#39;s testing to create an alternative to the Myriad -- to"
    },
    {
      "index": 243,
      "start_time": 1447630.0,
      "end_time": 1455860.0,
      "text": "create additional alternatives to the Myriad database. So we&#39;ll see how that goes."
    },
    {
      "index": 244,
      "start_time": 1455860.0,
      "end_time": 1464000.0,
      "text": "Larger impacts. So Greg Graff did an article in Nature Biotechnology a few months ago that"
    },
    {
      "index": 245,
      "start_time": 1464000.0,
      "end_time": 1471460.0,
      "text": "suggest that 8,700 U.S. gene patents with quote, unquote &quot;naturally occurring sequences&quot;"
    },
    {
      "index": 246,
      "start_time": 1471460.0,
      "end_time": 1478590.0,
      "text": "are still in force, about 41 percent of those human. Unfortunately, Greg, it&#39;s a great article,"
    },
    {
      "index": 247,
      "start_time": 1478590.0,
      "end_time": 1481900.0,
      "text": "and I would commend it to your attention, but his definition of naturally occurring"
    },
    {
      "index": 248,
      "start_time": 1481900.0,
      "end_time": 1487780.0,
      "text": "doesn&#39;t really map on to cDNA and gDNA distinction, so we don&#39;t really know -- and I&#39;ve been in"
    },
    {
      "index": 249,
      "start_time": 1487780.0,
      "end_time": 1493720.0,
      "text": "communication with him about this -- what percentage of the 8,700 are gDNAs that would"
    },
    {
      "index": 250,
      "start_time": 1493720.0,
      "end_time": 1499890.0,
      "text": "be knocked out and what percentage of cDNAs that remain valid. However, he does make the"
    },
    {
      "index": 251,
      "start_time": 1499890.0,
      "end_time": 1509030.0,
      "text": "important point in the article that the percentage of both cDNA and gDNA patents relative to"
    },
    {
      "index": 252,
      "start_time": 1509030.0,
      "end_time": 1514669.0,
      "text": "entirely synthetic patents began to decline precipitously around the time, I should note,"
    },
    {
      "index": 253,
      "start_time": 1514670.0,
      "end_time": 1521300.0,
      "text": "that NIH became heavily involved in persuading the PTO to issue much stricter examination"
    },
    {
      "index": 254,
      "start_time": 1521300.0,
      "end_time": 1527821.0,
      "text": "requirements for gene patents. This is not the remit of this particular group,"
    },
    {
      "index": 255,
      "start_time": 1527820.0,
      "end_time": 1533940.0,
      "text": "but in terms of the larger patent bar, I think that the biggest concern is not over gene"
    },
    {
      "index": 256,
      "start_time": 1533940.0,
      "end_time": 1541679.0,
      "text": "patents but over what the statements in Myriad, and also the Mayo case, mean for quote, unquote"
    },
    {
      "index": 257,
      "start_time": 1541680.0,
      "end_time": 1547741.0,
      "text": "&quot;purified&quot; large and small molecule therapeutics because that is an area where patent protection,"
    },
    {
      "index": 258,
      "start_time": 1547740.0,
      "end_time": 1551600.0,
      "text": "I think, the conventional wisdom has been patent protection is extremely important,"
    },
    {
      "index": 259,
      "start_time": 1551600.0,
      "end_time": 1558120.0,
      "text": "and the patent bar is particularly concerned about claims to proteins and antibodies that"
    },
    {
      "index": 260,
      "start_time": 1558120.0,
      "end_time": 1562970.0,
      "text": "aren&#39;t explicitly designated as synthetic. Going forward, I think most patent attorneys"
    },
    {
      "index": 261,
      "start_time": 1562970.0,
      "end_time": 1570270.0,
      "text": "will designate every patent claim that they can possibly think of as synthetic, but retroactively,"
    },
    {
      "index": 262,
      "start_time": 1570270.0,
      "end_time": 1575370.0,
      "text": "those claims that are not quote, unquote &quot;synthetic&quot; may be in peril."
    },
    {
      "index": 263,
      "start_time": 1575370.0,
      "end_time": 1586809.0,
      "text": "So, that&#39;s it. Any question either now, or you can email me at rai@law.duke.edu."
    },
    {
      "index": 264,
      "start_time": 1586810.0,
      "end_time": 1597411.0,
      "text": "Eric Green: Questions? Please step to the microphone,"
    },
    {
      "index": 265,
      "start_time": 1597410.0,
      "end_time": 1600220.0,
      "text": "anybody in back just step to a microphone, turn the microphone on."
    },
    {
      "index": 266,
      "start_time": 1600220.0,
      "end_time": 1601929.0,
      "text": "Female Speaker: [inaudible]"
    },
    {
      "index": 267,
      "start_time": 1601930.0,
      "end_time": 1605920.0,
      "text": "Eric Green: Wait, wait, wait -- go to -- they won&#39;t hear"
    },
    {
      "index": 268,
      "start_time": 1605920.0,
      "end_time": 1609131.0,
      "text": "you unless you are at a microphone and the microphone is on."
    },
    {
      "index": 269,
      "start_time": 1609130.0,
      "end_time": 1614530.0,
      "text": "Female Speaker: [inaudible] Ohio University. We recently had"
    },
    {
      "index": 270,
      "start_time": 1614530.0,
      "end_time": 1621870.0,
      "text": "a debate about this in a journal club, and I -- the point you mentioned about -- a cDNA"
    },
    {
      "index": 271,
      "start_time": 1621870.0,
      "end_time": 1629450.0,
      "text": "is really just a copy of a naturally-occurring molecule. It&#39;s just a common technique. Even"
    },
    {
      "index": 272,
      "start_time": 1629450.0,
      "end_time": 1635850.0,
      "text": "if you could use it for a therapeutic -- if you don&#39;t change it, okay, and you found it"
    },
    {
      "index": 273,
      "start_time": 1635850.0,
      "end_time": 1642179.0,
      "text": "from a naturally-occurring messenger RNA or other non-coding RNA, it is still just a copy;"
    },
    {
      "index": 274,
      "start_time": 1642180.0,
      "end_time": 1651141.0,
      "text": "there is nothing novel about it. So I would argue that the only way a cDNA could be patentable"
    },
    {
      "index": 275,
      "start_time": 1651140.0,
      "end_time": 1657549.0,
      "text": "is if they&#39;ve modified it in a way for a unique purpose, for a unique application. I don&#39;t"
    },
    {
      "index": 276,
      "start_time": 1657550.0,
      "end_time": 1665430.0,
      "text": "even know if you identify an mRNA, clone it into a cDNA, and it has a novel mutation for"
    },
    {
      "index": 277,
      "start_time": 1665430.0,
      "end_time": 1671781.0,
      "text": "a disease. That&#39;s still a naturally-occurring molecule that was in a tumor, or whatever"
    },
    {
      "index": 278,
      "start_time": 1671780.0,
      "end_time": 1679080.0,
      "text": "disease state the person was in. So I really am having a hard time wrapping myself around"
    },
    {
      "index": 279,
      "start_time": 1679080.0,
      "end_time": 1685750.0,
      "text": "what the -- why there is such a big misunderstanding between the genomic versus the cDNA, as opposed"
    },
    {
      "index": 280,
      "start_time": 1685750.0,
      "end_time": 1696309.0,
      "text": "to novel manipulations or natural mutations, maybe, that you can patent. It really -- so"
    },
    {
      "index": 281,
      "start_time": 1696310.0,
      "end_time": 1701131.0,
      "text": "I&#39;m glad you hit on that point, and I&#39;m glad you -- I know that somebody is out there saying,"
    },
    {
      "index": 282,
      "start_time": 1701130.0,
      "end_time": 1706210.0,
      "text": "what a minute, it&#39;s really still a natural product, the cDNA, if you don&#39;t manipulate"
    },
    {
      "index": 283,
      "start_time": 1706210.0,
      "end_time": 1711320.0,
      "text": "it. All you&#39;re doing is copying and putting it into a vector so you can sequence it."
    },
    {
      "index": 284,
      "start_time": 1711320.0,
      "end_time": 1715280.0,
      "text": "Arti Rai: So I think that the cDNA/gDNA distinction"
    },
    {
      "index": 285,
      "start_time": 1715280.0,
      "end_time": 1722470.0,
      "text": "has been one that is not universally subscribed to in terms of the doctrine, that it&#39;s not"
    },
    {
      "index": 286,
      "start_time": 1722470.0,
      "end_time": 1728799.0,
      "text": "entirely clear to a lot of people that, as a matter of doctrine, it makes a huge amount"
    },
    {
      "index": 287,
      "start_time": 1728800.0,
      "end_time": 1735471.0,
      "text": "of sense. That said, as I indicated, the cDNA patents are considered much more commercially"
    },
    {
      "index": 288,
      "start_time": 1735470.0,
      "end_time": 1740940.0,
      "text": "valuable, and I think that there&#39;s a certain element of economic policy also in patent"
    },
    {
      "index": 289,
      "start_time": 1740940.0,
      "end_time": 1745820.0,
      "text": "law that is, you know, inevitably apart of patent law."
    },
    {
      "index": 290,
      "start_time": 1745820.0,
      "end_time": 1750220.0,
      "text": "Male Speaker: So could you clarify, when you are talking"
    },
    {
      "index": 291,
      "start_time": 1750220.0,
      "end_time": 1755010.0,
      "text": "about cDNA patents, are you talking specifically about Myriad cDNA patents, or the set of cDNA"
    },
    {
      "index": 292,
      "start_time": 1755010.0,
      "end_time": 1758130.0,
      "text": "patents that -- because there are a lot of cDNA patents, right?"
    },
    {
      "index": 293,
      "start_time": 1758130.0,
      "end_time": 1762160.0,
      "text": "Arti Rai: The set of cDNA patents are -- those are all"
    },
    {
      "index": 294,
      "start_time": 1762160.0,
      "end_time": 1762910.0,
      "text": "still valid."
    },
    {
      "index": 295,
      "start_time": 1762910.0,
      "end_time": 1764700.0,
      "text": "Male Speaker: Right, but okay --"
    },
    {
      "index": 296,
      "start_time": 1764700.0,
      "end_time": 1767120.0,
      "text": "Arti Rai: Yeah. So, yeah, absolutely -- sorry, follow"
    },
    {
      "index": 297,
      "start_time": 1767120.0,
      "end_time": 1767419.0,
      "text": "up."
    },
    {
      "index": 298,
      "start_time": 1767420.0,
      "end_time": 1770781.0,
      "text": "Male Speaker: No, no, so my question was, is your feeling"
    },
    {
      "index": 299,
      "start_time": 1770780.0,
      "end_time": 1777230.0,
      "text": "that, you know, because there are so many cDNA patents out there, outside of this -- the"
    },
    {
      "index": 300,
      "start_time": 1777230.0,
      "end_time": 1783120.0,
      "text": "ones that Myriad has, that the Supreme Court didn&#39;t want to take them all down at the same"
    },
    {
      "index": 301,
      "start_time": 1783120.0,
      "end_time": 1788370.0,
      "text": "time that it was taking down -- you know, by restricting it to the gDNA and leaving"
    },
    {
      "index": 302,
      "start_time": 1788370.0,
      "end_time": 1793970.0,
      "text": "the cDNAs open, it was a sort of Solomonic decision, or whatever --"
    },
    {
      "index": 303,
      "start_time": 1793970.0,
      "end_time": 1797000.0,
      "text": "Arti Rai: Yeah, it was I think it was a Solomonic decision,"
    },
    {
      "index": 304,
      "start_time": 1797000.0,
      "end_time": 1802309.0,
      "text": "I&#39;m not sure they fully understood all the implications. But I think it was clear to"
    },
    {
      "index": 305,
      "start_time": 1802310.0,
      "end_time": 1811241.0,
      "text": "them that drawing that distinction would leave the biotech industry largely satisfied, and"
    },
    {
      "index": 306,
      "start_time": 1811240.0,
      "end_time": 1820799.0,
      "text": "also satisfy the concerns of researchers about gDNA claims. So it was a way to try to balance"
    },
    {
      "index": 307,
      "start_time": 1820800.0,
      "end_time": 1827821.0,
      "text": "the interests of the commercial community and research -- the research community."
    },
    {
      "index": 308,
      "start_time": 1827820.0,
      "end_time": 1831830.0,
      "text": "Male Speaker: I wonder if you could comment a little bit"
    },
    {
      "index": 309,
      "start_time": 1831830.0,
      "end_time": 1836450.0,
      "text": "further on this distinction of diagnostic versus therapeutic, especially in cases of"
    },
    {
      "index": 310,
      "start_time": 1836450.0,
      "end_time": 1841549.0,
      "text": "oncology where that line is getting blurred, or in rare diseases where oligonucleotides"
    },
    {
      "index": 311,
      "start_time": 1841550.0,
      "end_time": 1845281.0,
      "text": "and others are -- actually, the diagnostic is intrinsically linked to the therapeutic"
    },
    {
      "index": 312,
      "start_time": 1845280.0,
      "end_time": 1845280.0,
      "text": "--"
    },
    {
      "index": 313,
      "start_time": 1845280.0,
      "end_time": 1849179.0,
      "text": "Arti Rai: Yes, so I think it is going to be very interesting"
    },
    {
      "index": 314,
      "start_time": 1849180.0,
      "end_time": 1857141.0,
      "text": "because, yes, certainly with companion diagnostics, I think it&#39;s going to -- there&#39;s going to"
    },
    {
      "index": 315,
      "start_time": 1857140.0,
      "end_time": 1863799.0,
      "text": "be pressure brought to bear on that distinction, because with companion diagnostics in particular,"
    },
    {
      "index": 316,
      "start_time": 1863800.0,
      "end_time": 1870341.0,
      "text": "some of those patents could be quite commercially important. And -- so query how that will all"
    },
    {
      "index": 317,
      "start_time": 1870340.0,
      "end_time": 1873990.0,
      "text": "work out. I think some people are rightly concerned about that question."
    },
    {
      "index": 318,
      "start_time": 1873990.0,
      "end_time": 1879299.0,
      "text": "Male Speaker: Arti, I was wondering, do you have any sense"
    },
    {
      "index": 319,
      "start_time": 1879300.0,
      "end_time": 1885471.0,
      "text": "of what Ambry, GeneDx, and the others, what their response has been since the suits? I"
    },
    {
      "index": 320,
      "start_time": 1885470.0,
      "end_time": 1890409.0,
      "text": "mean, specifically, are they still offering the tests, and if any of them are still offering"
    },
    {
      "index": 321,
      "start_time": 1890410.0,
      "end_time": 1896031.0,
      "text": "it, do you -- you know, are you aware of any reports of sort of the quality of the annotation"
    },
    {
      "index": 322,
      "start_time": 1896030.0,
      "end_time": 1898370.0,
      "text": "going on since they don&#39;t have access to the Myriad databases?"
    },
    {
      "index": 323,
      "start_time": 1898370.0,
      "end_time": 1901309.0,
      "text": "Arti Rai: I believe they are still offering the tests,"
    },
    {
      "index": 324,
      "start_time": 1901310.0,
      "end_time": 1909371.0,
      "text": "I do not know about -- I know they dispute the Myriad numbers. I don&#39;t know specifically"
    },
    {
      "index": 325,
      "start_time": 1909370.0,
      "end_time": 1916440.0,
      "text": "about -- as I understand it, they put their VUS rates significantly lower than the Myriad"
    },
    {
      "index": 326,
      "start_time": 1916440.0,
      "end_time": 1923730.0,
      "text": "numbers. And, in fact, one of the briefs argued that Myriad was unfairly maligning their tests,"
    },
    {
      "index": 327,
      "start_time": 1923730.0,
      "end_time": 1927730.0,
      "text": "and that was part of the monopolization claim, although I&#39;m not entirely clear as to how"
    },
    {
      "index": 328,
      "start_time": 1927730.0,
      "end_time": 1929320.0,
      "text": "that fit into the monopolization question."
    },
    {
      "index": 329,
      "start_time": 1929320.0,
      "end_time": 1932309.0,
      "text": "Male Speaker: I can confirm that they&#39;re still offering"
    },
    {
      "index": 330,
      "start_time": 1932310.0,
      "end_time": 1937670.0,
      "text": "the tests. Many of us are sending it to Myriad&#39;s competitors. I&#39;d be interested in what Bob"
    },
    {
      "index": 331,
      "start_time": 1937670.0,
      "end_time": 1943701.0,
      "text": "Nussbaum might think. You know, that claim of 20 to 30 percent VUS is, I think -- my"
    },
    {
      "index": 332,
      "start_time": 1943700.0,
      "end_time": 1952380.0,
      "text": "perception is, is grossly inflated. Certainly, what Ambry has on their website is a estimate"
    },
    {
      "index": 333,
      "start_time": 1952380.0,
      "end_time": 1957970.0,
      "text": "that they&#39;ll have -- I think it&#39;s around a 5 percent VUS rate, which seems more realistic"
    },
    {
      "index": 334,
      "start_time": 1957970.0,
      "end_time": 1960340.0,
      "text": "to me, but I was wondering what Bob thought."
    },
    {
      "index": 335,
      "start_time": 1960340.0,
      "end_time": 1964080.0,
      "text": "Male Speaker: Well, there&#39;s a paper published in 2009, first"
    },
    {
      "index": 336,
      "start_time": 1964080.0,
      "end_time": 1970750.0,
      "text": "author Easton, which includes four authors, I believe, from Myriad that have a lower VUS"
    },
    {
      "index": 337,
      "start_time": 1970750.0,
      "end_time": 1977630.0,
      "text": "rate than they&#39;re claiming now Ambry would have, and based on public databases back in"
    },
    {
      "index": 338,
      "start_time": 1977630.0,
      "end_time": 1985090.0,
      "text": "2009. So although Myriad may have improved their VUS rate, it is sort of hard for anyone"
    },
    {
      "index": 339,
      "start_time": 1985090.0,
      "end_time": 1990440.0,
      "text": "to know because it is a closed shop. But I think that it&#39;s hard for me to imagine why"
    },
    {
      "index": 340,
      "start_time": 1990440.0,
      "end_time": 1995840.0,
      "text": "the VUS rate would have jumped in the last four years."
    },
    {
      "index": 341,
      "start_time": 1995840.0,
      "end_time": 1997380.0,
      "text": "[laughter]"
    },
    {
      "index": 342,
      "start_time": 1997380.0,
      "end_time": 2002409.0,
      "text": "So that&#39;s kind of my feeling about it."
    },
    {
      "index": 343,
      "start_time": 2002410.0,
      "end_time": 2007231.0,
      "text": "Arti Rai: Thank you."
    },
    {
      "index": 344,
      "start_time": 2007230.0,
      "end_time": 2009690.0,
      "text": "Eric Green: Any other -- thank you, Arti. That was terrific."
    },
    {
      "index": 345,
      "start_time": 2009690.0,
      "end_time": 2010500.0,
      "text": "So we&#39;re breaking?"
    },
    {
      "index": 346,
      "start_time": 2010500.0,
      "end_time": 2013520.0,
      "text": "Rudy Pozzatti: We are breaking for lunch for the rest of"
    },
    {
      "index": 347,
      "start_time": 2013520.0,
      "end_time": 2017789.0,
      "text": "the audience, but for the council members, we are going to have your photograph taken."
    },
    {
      "index": 348,
      "start_time": 2017790.0,
      "end_time": 2021901.0,
      "text": "So if you could please stay at the table, the photographer will come in here -- I think"
    },
    {
      "index": 349,
      "start_time": 2021900.0,
      "end_time": 2026860.0,
      "text": "we have a room reserved for the picture. And then after that, you can go to lunch, and"
    },
    {
      "index": 350,
      "start_time": 2026860.0,
      "end_time": 2036860.0,
      "text": "can we please come back at 1:15 to resume. Okay."
    }
  ]
}